Cinctive Capital Management LP Takes $3.67 Million Position in 10x Genomics, Inc. (NASDAQ:TXG)

Cinctive Capital Management LP purchased a new stake in 10x Genomics, Inc. (NASDAQ:TXG - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 162,585 shares of the company's stock, valued at approximately $3,671,000. Cinctive Capital Management LP owned 0.13% of 10x Genomics at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the company. Swedbank AB acquired a new stake in shares of 10x Genomics in the first quarter valued at approximately $675,000. SG Americas Securities LLC increased its holdings in 10x Genomics by 604.9% in the 2nd quarter. SG Americas Securities LLC now owns 101,344 shares of the company's stock valued at $1,971,000 after buying an additional 86,967 shares during the period. Mirador Capital Partners LP raised its position in shares of 10x Genomics by 115.0% in the 2nd quarter. Mirador Capital Partners LP now owns 61,967 shares of the company's stock valued at $1,205,000 after buying an additional 33,142 shares in the last quarter. SteelPeak Wealth LLC bought a new stake in shares of 10x Genomics during the 2nd quarter worth approximately $413,000. Finally, Sumitomo Mitsui Trust Holdings Inc. boosted its position in shares of 10x Genomics by 69.6% during the 2nd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 6,143,067 shares of the company's stock worth $119,483,000 after acquiring an additional 2,521,289 shares in the last quarter. Institutional investors and hedge funds own 84.68% of the company's stock.

10x Genomics Trading Down 3.9 %

Shares of 10x Genomics stock traded down $0.64 on Tuesday, reaching $15.83. The stock had a trading volume of 507,410 shares, compared to its average volume of 1,743,353. The business's 50 day moving average is $16.89 and its two-hundred day moving average is $19.50. 10x Genomics, Inc. has a 1 year low of $12.95 and a 1 year high of $57.90.

10x Genomics (NASDAQ:TXG - Get Free Report) last issued its quarterly earnings data on Tuesday, October 29th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.34) by $0.04. 10x Genomics had a negative return on equity of 25.07% and a negative net margin of 28.93%. The company had revenue of $151.65 million for the quarter, compared to the consensus estimate of $158.84 million. During the same quarter last year, the business posted ($0.51) earnings per share. The firm's revenue was down 1.3% compared to the same quarter last year. On average, equities analysts expect that 10x Genomics, Inc. will post -1.4 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have recently weighed in on TXG. Morgan Stanley reduced their price target on shares of 10x Genomics from $50.00 to $46.00 and set an "overweight" rating on the stock in a research note on Tuesday, August 13th. Barclays lowered their price target on shares of 10x Genomics from $21.00 to $19.00 and set an "overweight" rating for the company in a report on Friday, November 1st. Stephens reissued an "overweight" rating and set a $30.00 price objective on shares of 10x Genomics in a report on Thursday, October 10th. Canaccord Genuity Group lowered their target price on 10x Genomics from $32.00 to $20.00 and set a "buy" rating for the company in a report on Thursday, October 10th. Finally, Leerink Partnrs raised 10x Genomics to a "strong-buy" rating in a research note on Tuesday, September 3rd. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $29.19.

10x Genomics Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.